Arch Therapeutics Inc is a pioneering medical device company that prioritizes patient health and safety. With an unwavering commitment to advancing technology, Arch Therapeutics Inc focuses on developing innovative solutions for surgical and therapeutic applications. The company's corporate philosophy revolves around employing cutting-edge research and development to address unmet needs in the medical field. Arch Therapeutics Inc places great emphasis on collaboration with healthcare professionals, ensuring that their products meet the highest standards of efficacy and performance. With a strong dedication to improving patient outcomes, Arch Therapeutics Inc embodies values of excellence, integrity, and innovation in all aspects of their operations.

Arch Therapeutics Inc is primarily present in the United States. As a biotechnology company, Arch Therapeutics Inc focuses on developing innovative products to address unmet medical needs. With its headquarters located in Framingham, Massachusetts, the company primarily operates within the United States. By leveraging its proprietary self-assembling peptide technology platform, Arch Therapeutics Inc aims to revolutionize the field of wound healing and surgical adhesives. With a strong emphasis on research and development, the company is committed to advancing medical solutions that enhance patient outcomes and drive growth in the healthcare sector.

Arch Therapeutics Inc has achieved several significant milestones in recent years. One notable accomplishment is the completion of successful clinical trials for its flagship product, AC5 Topical Hemostat. This innovative hemostatic device has garnered attention and recognition from the medical community for its ability to rapidly control bleeding in both surgical and trauma settings. Arch Therapeutics Inc has also secured key partnerships and collaborations with leading healthcare organizations, further establishing its position in the market. Additionally, the company has received regulatory approvals and patents, highlighting its commitment to innovation and intellectual property protection. These achievements highlight Arch Therapeutics Inc's dedication to advancing medical solutions and improving patient outcomes.

Arch Therapeutics Inc is a biotechnology company based in the United States. Established in 2006, the company specializes in developing and commercializing novel medical devices. Arch Therapeutics is focused on addressing unmet clinical needs by providing innovative solutions for hemostasis and sealing in surgical and interventional medicine. With its flagship product, AC5 Advanced Wound System, the company aims to revolutionize surgical procedures by improving patient outcomes and reducing healthcare costs. Arch Therapeutics Inc has demonstrated a commitment to research and development, aiming to create groundbreaking healthcare solutions. Their dedication to innovation and advancement makes Arch Therapeutics Inc a prominent player in the biotechnology industry.

The main competitors of Arch Therapeutics Inc in the market include companies like Johnson & Johnson, Baxter International, and Medtronic.

Arch Therapeutics Inc is primarily active in the biotechnology and medical device industries.

The business model of Arch Therapeutics Inc revolves around the development and commercialization of novel wound healing and surgical products. This Massachusetts-based biotechnology company focuses on creating innovative solutions for the management of bleeding and fluid loss during surgical procedures. Arch Therapeutics aims to provide superior surgical tools and technologies to improve patient outcomes and enhance surgical performance. This company's dedication to advancing medical care through its cutting-edge products highlights its commitment to revolutionizing the field of surgical medicine.

مُعامل القيمة السوقية إلى الأرباح لـ Arch Therapeutics هو ٠٫٠١.

مُعامِل القيمة إلى المبيعات Arch Therapeutics هو ٠٫٠١.

نقاط جودة AlleAktien لـ Arch Therapeutics هي 6/10.

المتوقعة Arch Therapeutics الإيرادات هي ١٤٠٫٧٦ مليون. USD.

صافي الربح المتوقعة Arch Therapeutics هو ١١٢٫١٨ مليون. USD.

Arch Therapeutics is a biotechnology company that focuses on the development and marketing of therapeutic solutions for controlling bleeding and tissue formation. The company is headquartered in Framingham, Massachusetts and is listed on the Nasdaq stock exchange under the ticker symbol "ARTH".

يوزع Arch Therapeutics أرباحًا قدرها 0 USD من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ Arch Therapeutics في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـArch Therapeutics هو US03939W1099.

رمز WKN لـ Arch Therapeutics هو A1W2JT.

الرمز المُختصر لـ Arch Therapeutics هو ARTH.

خلال آخر 12 شهراً، دفعت Arch Therapeutics توزيعات أرباح بقيمة . وهذا يعادل عائد توزيعات أرباح يقارب . ومن المتوقع أن تدفع Arch Therapeutics خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ0 USD.

نسبة توزيعات الأرباح الحالية لـ Arch Therapeutics هي .

Arch Therapeutics يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر .

Arch Therapeutics دفعت توزيعات الأرباح كل عام خلال الـ0 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة 0 USD. وهذا يعادل عائد توزيعات أرباح قدره 0 %.

Arch Therapeutics يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة 0 USD من Arch Therapeutics المُعلن عنها في ٢١‏/٩‏/٢٠٢٤، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ٢١‏/٩‏/٢٠٢٤.

تم توزيع آخر دفعة من الأرباح بتاريخ ٢١‏/٩‏/٢٠٢٤.

في العام 2023، وزعت Arch Therapeutics 0 USD كأرباح أسهم.

يتم توزيع أرباح Arch Therapeutics بالعملة USD.